
A study was done to compare the efficacy of dorzolamide 2% timolol 0.5%fixed combination versus brinzolamide 1% brimonidine 0.2% fixed combination therapy in patients of primary open angle glaucoma. A randomized, open label, comparative, parallel group study was conducted on 40 patients of POAG attending the Outpatient Department of Ophthalmology, Government Medical College, Patiala. Patients selected were then randomised into two groups of 20 each. Baseline IOP was recorded at 9 am and 11 am on day 0 of the study.Group A: Fixed drug combination of Dorzolamide2%/ Timolol 0.5% (DTFC) dosed twice daily at 9 am and 9 pm .This group instilled 1 drop of DTFC ophthalmic solution into study eye twice daily at 9.00 a.m. and 9.00 p.m. for 6 weeks. Group B: Fixed drug combination of Brinzolamide 1%/ Brimonidine 0.2% (BBFC) dosed twice daily at 9 am and 9 pm. This group instilled 1 drop of BBFC ophthalmic solution into study eye twice daily at 9.00 a.m. and 9.00 p.m. for 6 weeks. Patients were then called for follow up at 2nd week, 4th week and 6th week during the study period and IOP recorded at 9 am and 11 am in the OPD. In Group A (DTFC), mean IOP at visit 1 ( baseline) at 9:00 AM was 27.00 ± 1.78 mm Hg, at 11:00 AM was 27.50 ± 1.91 mm Hg and mean IOP at all time points was 27.25 ± 1.81 mm Hg. There was no statistically significant variation in the mean IOP at any of the follow up visit in group A (p > 0.05). In Group B (BBFC), mean IOP at visit 1 ( baseline) at 9:00 AM was 26.85 ± 1.98 mm Hg, at 11:00 AM was 27.10 ± 2.17 mm Hg and mean IOP at all time points was 26.98 ± 2.04 mm Hg.There was no statistically significant variation in the mean IOP at any of the follow up visit in group A (p > 0.05).The reduction in mean IOP at visit 6 weeks in group A (DTFC) was 10.32 mm Hg (37.87%) and in group B (BBFC) was 9.50 mm Hg (35.21%). The reduction in mean IOP was comparable between the two groups. The difference was statistically non significant (p > 0.05).